Orgenesis Begins Trading on OTCQX
Orgenesis Inc, a prominent player in the biotech sector dedicated to enhancing cell and gene therapies, has recently made a significant shift by commencing trading on the OTCQX Best Market under the ticker symbol "ORGS". This transition comes after the company faced delisting from the Nasdaq Stock Market due to not meeting the necessary stockholders' equity requirement. Despite this setback, Orgenesis is committed to resolving this issue and plans to reapply for a Nasdaq listing as soon as possible.
Commitment to Corporate Governance
The change to OTCQX signifies Orgenesis' determination to uphold the highest standards of corporate governance and transparency, even in the face of challenges. The Company believes that trading under the OTCQX will provide ongoing access to liquidity for its shareholders while it works diligently to rectify the equity shortfall.
CEO Insights on Future Plans
Vered Caplan, the CEO of Orgenesis, emphasized that although the company is disappointed by the delisting, its focus remains on future growth. Caplan pointed out that the Company's expanding network of partnerships with hospitals and research institutions globally will support its mission to make cell and gene therapies more affordable and accessible. Orgenesis is making remarkable progress in developing innovative therapies through its decentralized platform.
Innovative Decentralized Cell Processing Platform
Orgenesis is leading the way in the biotech industry with its unique Decentralized Cell Processing (DCP) platform, which is designed to revolutionize patient access to advanced therapies. This platform offers a scalable, cost-effective solution for producing these therapies right where they are needed, addressing the limitations inherent in traditional centralized processing methods.
Partnerships Enhancing Patient Access
By collaborating with leading hospitals and research institutions worldwide, Orgenesis aims to significantly enhance patient access to potentially life-saving therapies. The growing demand for cell and gene therapies, coupled with Orgenesis' innovative approach, positions the company for substantial growth and value creation in the coming years.
About Orgenesis Inc
Founded in 2012, Orgenesis has steadfastly focused on unlocking the potential of cell and gene therapies. Since its introduction of the decentralized processing model in 2020, the company has aimed to bridge the gap between academia, hospitals, and industry. Orgenesis is dedicated to advancing its therapies toward eventual commercialization by partnering with key stakeholders. This collaboration allows for a rapid, harmonized approach to bringing essential therapies to patients efficiently and cost-effectively.
Frequently Asked Questions
What recent changes have occurred for Orgenesis Inc?
Orgenesis Inc has transitioned to trading on the OTCQX Best Market after being delisted from the Nasdaq due to not meeting stockholders' equity requirements.
What does OTCQX signify for Orgenesis?
Trading on OTCQX demonstrates Orgenesis' commitment to maintaining high levels of corporate governance and transparency while resolving its equity shortfall.
What is the Decentralized Cell Processing platform?
The Decentralized Cell Processing platform developed by Orgenesis offers a cost-effective and scalable solution for producing advanced therapies at or near patient care sites.
How does Orgenesis plan to enhance patient access?
Orgenesis is expanding partnerships with hospitals and research institutions to enhance patient access to affordable cell and gene therapies.
What is the future outlook for Orgenesis?
Orgenesis plans to improve its financial standing to reapply for a Nasdaq listing and continue its innovative developments in cell therapy.
IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com
